Previous 10 | Next 10 |
TCR2 Therapeutics (TCRR): Q3 GAAP EPS of -$0.56.Cash, cash equivalents, and investments of $246.7M.Press Release For further details see: TCR2 Therapeutics reports Q3 results
- Consistent progress of TC-210 with interim update from Phase 1/2 trial anticipated in 4Q20 - Additional clinical sites to include UCSF Medical Center and Princess Margaret Cancer Centre in the TC-210 Phase 1/2 clinical trial - Agreement with ElevateBio for additional manufacturi...
TCR2 Therapeutics (TCRR) has established a manufacturing partnership with ElevateBio, to leverage the extensive technical capabilities at ElevateBio BaseCamp, a cell and gene therapy manufacturing facility based in Waltham, MA. The partnership will focus on the production of TC-210, TCR2 ...
- ElevateBio BaseCamp to support anticipated TC-210 Phase 2 clinical trial demand CAMBRIDGE, Mass., Nov. 10, 2020 (GLOBE NEWSWIRE) -- TCR 2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage immunotherapy company developing a pipeline of novel T cell therapies for patients sufferi...
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha, Apple Po...
CAMBRIDGE, Mass., Sept. 29, 2020 (GLOBE NEWSWIRE) -- TCR 2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage immunotherapy company with a pipeline of novel T cell therapies for patients suffering from cancer, today announced that management will participate in a fireside chat at the Je...
CAMBRIDGE, Mass., Sept. 08, 2020 (GLOBE NEWSWIRE) -- TCR 2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage immunotherapy company with a pipeline of novel T cell therapies for patients suffering from cancer, today announced that Ian Somaiya, Chief Financial Officer of TCR 2 Therape...
TCR2 Therapeutics (NASDAQ: TCRR ) : Q2 GAAP EPS of -$0.67 misses by $0.03 . More news on: TCR2 Therapeutics Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
- TC-210 patient with partial response confirmed by independent central review and tumor regression improved further from 42% to 75% - Began dosing of TC-110 in the Phase 1/2 trial for patients with CD19+ NHL or adult ALL - Addition of MD Anderson Cancer Center, a leading clinical site...
The following slide deck was published by TCR2 Therapeutics Inc. in conjunction with this Read more ...
News, Short Squeeze, Breakout and More Instantly...
TCR2 Therapeutics Inc. Company Name:
TCRR Stock Symbol:
NASDAQ Market:
TCR2 Therapeutics Inc. Website:
CAMBRIDGE, Mass., May 11, 2023 (GLOBE NEWSWIRE) -- TCR 2 Therapeutics Inc. (Nasdaq: TCRR) (TCR 2 or the Company), a clinical-stage cell therapy company with a pipeline of novel next-generation T cell therapies for patients suffering from solid tumors, today announced financial results for...
NEW YORK, NY / ACCESSWIRE / April 2, 2023 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Radius Global Infrastructure, Inc....
NEW YORK, NY / ACCESSWIRE / March 30, 2023 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: U.S. Xpress Enterprises, Inc. (NYSE:...